Search Results

You are looking at 1 - 10 of 471 items for :

  • blood-based biomarker x
  • Refine by Access: All content x
Clear All
Free access

Luke A Selth, Wayne D Tilley, and Lisa M Butler

challenges The identification of miRNAs in body fluids, including the blood, has triggered considerable excitement in the biomarker field. We believe that this excitement is well founded: based on their stability and relative ease of detection, circulating

Free access

Aura D Herrera-Martínez, Leo J Hofland, María A Gálvez Moreno, Justo P Castaño, Wouter W de Herder, and Richard A Feelders

pathway inhibitors’, ‘everolimus’, ‘temozolamide’, ‘alkylant-based chemotherapy’, ‘somatostatin analogs’, ‘sunitinib’, ‘immunotherapy’, ‘molecular biomarkers’, ‘epidermal growth factor receptor’, ‘vascular endothelial growth factor’, ‘Interleukin-8

Free access

Maria Chiara Zatelli, Erika Maria Grossrubatscher, Elia Guadagno, Concetta Sciammarella, Antongiulio Faggiano, and Annamaria Colao

et al . 2016 ) or phosphorylated histone H3 assessment ( Villani et al . 2016 ). Besides tissue-based characteristics, blood-based biomarkers have been considered, also due to easy accessibility of the compartment and possibility of multiple sampling

Free access

Irvin M Modlin, Ignat Drozdov, Daniele Alaimo, Stephen Callahan, Nancy Teixiera, Lisa Bodei, and Mark Kidd

levels ( Lecci et al . 2006 ). Given the limited accuracy of the currently available biomarkers and the known limitations of single analyte measurements in clinical science ( Hood & Tian 2012 , Curtis et al . 2013 ), we have developed a blood-based

Free access

Veronica R Placencio-Hickok, Anisha Madhav, Sungjin Kim, Frank Duong, Bryan Angara, Zhenqiu Liu, and Neil A Bhowmick

been described as a serum biomarker in breast, colon, and prostate cancer ( Li et al. 2000 , Takahashi et al. 2001 , Svatek et al. 2008 , Fujita et al. 2009 ). In this study, we examined sCD105 as a blood-based prognostic biomarker for

Open access

Alexa Childs, Christopher D Steele, Clare Vesely, Francesca M Rizzo, Leah Ensell, Helen Lowe, Pawan Dhami, Heli Vaikkinen, Tu Vinh Luong, Lucia Conde, Javier Herrero, Martyn Caplin, Christos Toumpanakis, Christina Thirlwell, John A Hartley, Nischalan Pillay, and Tim Meyer

resistance allele in NSCLC ( Maheswaran et al. 2008 ). In SCLC, a pretreatment CTC-based biomarker has been shown to predict sensitivity to first-line chemotherapy ( Carter et al. 2017 ). Neuroendocrine neoplasms (NEN) represent a heterogeneous disease

Free access

Mark Kidd, Ignat Drozdov, and Irvin Modlin

monoanalyte strategy, we developed a genetic biomarker assay in blood for GEP–NETs based upon qRT-PCR measurement of 51 circulating NET marker genes. Normalized gene expression is classified using four different learning algorithms (support vector machine

Free access

Li Li, Heidi L Weiss, Jing Li, Zhengyi Chen, Leslie Donato, and B Mark Evers

been postulated, based on limited clinical data, that circulating levels of NT may serve as a biomarker for CRC, the risk association of pro-NT with CRC has not been explicitly and fully examined. Methods Study population To test the

Restricted access

Mojun Zhu, Karl R Sorenson, Rebecca Liu, Bonnie E Gould Rothberg, and Thorvardur R Halfdanarson

-off points. Other peripheral blood-based biomarkers such as NLR face similar challenges as testing methods, and cut-off points tend to differ by institution. In the class of cellular markers, the expression of HSP90 ( Gamboa et al. 2020 ), α

Free access

Vanessa W Lim, Jun Li, Yinhan Gong, Aizhen Jin, Jian-Min Yuan, Eu Leong Yong, and Woon-Puay Koh

causality bias. Cancer cases were identified using a comprehensive nationwide cancer registry. The limitations of this study are that the results are based on blood samples collected at a single time point, as the natural fluctuation of biomarkers that most